Table 3 Characteristics of analysed clinical trial registrations
Variable (N of trials with reported variable) | N (%)a |
|---|---|
Clinical trial registry (N = 927) | |
Chinese Clinical Trials Registry (ChiCTR) | 581 (63) |
286 (30) | |
EU Clinical Trials Register | 21 (2.2) |
Australian New Zealand Clinical Trials Registry (ANZCTR) | 9 (1) |
ISRCTN | 8 (0.9) |
IRCT | 8 (0.9) |
Other | 14 (1.5) |
Recruitment status (N = 915) | |
Not recruiting | 453 (50) |
Recruiting | 441 (48) |
Authorized | 21 (2.2) |
Minimal age of participants (N = 744) | |
18 years | 532 (72) |
0 years | 26 (3.5) |
14 years | 18 (2.4) |
16 years | 15 (2) |
1 year | 13 (1.7) |
Other | 140 (15) |
Maximal age of participants (N = 663) | |
Not applicable/no upper limit | 197 (30) |
80 years | 59 (9) |
75 years | 55 (8.2) |
90 years | 42 (6.3) |
65 years | 32 (4.8) |
Other | 278 (42) |
Eligibility of participants based on sex (N = 921) | |
Both men and women | 892 (97) |
Only men | 18 (1.9) |
Only women | 11 (1.2) |
Self-reported study type (N = 927) | |
Interventional | 535 (58) |
Observational | 303 (33) |
Diagnostic test | 35 (3.8) |
Observational (patient registry) | 19 (2) |
Epidemiological research | 10 (1) |
Other | 25 (2.7) |
Location of trials located in single countries (N = 825) | |
China | 622 (63) |
United States | 33 (4.0) |
France | 21 (2.5) |
Italy | 17 (2.1) |
United Kingdom | 10 (1.2) |
Other | 122 (15) |
Tested interventions (N = 535) | |
Hydroxychloroquine | 39 (7.2) |
Chloroquine | 16 (3.0) |
Tocilizumab | 10 (1.9) |
Lopinavir/ritonavir combination | 10 (1.9) |
Convalescent plasma | 9 (1.7) |
Other | 451 (84) |